ライフサイエンスコーパス: minoxidil

1 fect, but prevented stimulation by 10 microM minoxidil.

2 l, nicardipine, nifedipine, enalaprilat, and minoxidil.

3 oses of the 5-alpha reductase inhibitors and minoxidil.

4 hair follicles, oral finasteride and topical minoxidil.

5 ormulations of oral minoxidil and sublingual minoxidil.

6 ional regret was reported with anthralin and minoxidil.

7 Minoxidil (0.1-100 microM, p<0.001), NNC 55-0118 (1 mM,

8 .1 hairs/cm2; 95% CI, 5.1-9.3 hairs/cm2) and minoxidil (0.25 mg/d [mean difference, 23.7 hairs/cm2; 9

9 w- to moderate-quality evidence that topical minoxidil (2% and 5%) was associated with improvements i

10 ants were randomized 1:1 into 2 groups: oral minoxidil, 5 mg, daily and topical placebo solution; or

11 In this study, oral minoxidil, 5 mg, once per day for 24 weeks did not demon

12 topical placebo solution; or 1 mL of topical minoxidil, 5%, twice daily and oral placebo for 24 weeks

13 did not demonstrate superiority over topical minoxidil, 5%, twice per day in men with AGA.

14 developed tubular cysts, we demonstrate that minoxidil, a potent autophagy activator and an FDA-appro

15 Treatment with minoxidil, an inhibitor of hypoxia-induced sarcoma metas

16 e lag time and increase skin permeability to minoxidil and acyclovir by more than three-fold compared

17 R particles can increase topical delivery of minoxidil and acyclovir to improve modulation of hair gr

18 particles also improved topical delivery of minoxidil and acyclovir, which resulted in an increase o

19 ve potassium (K(ATP)) channel openers, e.g., minoxidil and diazoxide, can induce hair growth, their m

20 These K(+) currents were augmented by minoxidil and pinacidil and attenuated by glibenclamide

21 dil, such as compounded formulations of oral minoxidil and sublingual minoxidil.

22 contain K(ATP) channels that can respond to minoxidil and that tolbutamide may suppress hair growth

23 ugs for androgenetic alopecia (AGA), namely, minoxidil and the two 5-alpha reductase inhibitors dutas

24 Minoxidil and tolbutamide, a K(ATP) channel blocker, opp

25 Patient was asked to avoid future use of Minoxidil and was started on oral eplerenone therapy 50

26 ment for androgenic alopecia with topical 5% Minoxidil application on scalp two times a day.

27 Using minoxidil as an initial template for structural modifica

28 K(ATP) channel openers (minoxidil, cromakalim, and pinacidil) increased cellular

29 0.001) and abolished the effect of 10 microM minoxidil, diazoxide and NNC 55-0118; glibenclamide (10

30 it, indications for LDOM compared to topical minoxidil, dosing for adults (18 years and older) and ad

31 mechanisms but used for similar indications (minoxidil for alopecia and tamsulosin hydrochloride for

32 has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment.

33 Despite the long-standing use of minoxidil for balding, its mechanism is unclear; suggest

34 However, the efficacy of oral minoxidil for male AGA is yet to be evaluated in compara

35 oxidil vs oral minoxidil, the safety of oral minoxidil for patients with a history of allergic contac

36 of 33 participants were enrolled in the oral minoxidil group and 35 in the topical treatment group.

37 The most common adverse effects in the oral minoxidil group were hypertrichosis (22 of 45 [49%]) and

38 as significantly more effective than topical minoxidil (in 2% [mean difference, 32.1 hairs/cm2; 95% C

39 o potassium channel opener drugs (pinacidil, minoxidil) in both chambers of the heart and in VSM.

40 o potassium channel opener drugs (pinacidil, minoxidil) in both chambers of the heart and in VSM.

41 opecia may begin in adolescence, and topical minoxidil is effective at retarding further hair loss.

42 suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients

43 s well as mTOR-independent carbamazepine and minoxidil, markedly attenuated cyst formation and restor

44 gnificantly more efficacious than 2% topical minoxidil (mean difference, 20.7 hairs/cm2; 95% CI, 9.5-

45 Stability studies revealed that minoxidil nanofiber was stable if stored at room tempera

46 ysis, oral minoxidil was superior to topical minoxidil on the vertex (24%; 95% CI, 0 to 48; P = .04)

47 ATP) channels, Kir6.2/SUR1 and Kir6.1/SUR2B; minoxidil only stimulates SUR2 channels.

48 number of anagen-phase hair follicles after minoxidil or acyclovir treatment, respectively.

49 Attenuating collagen cross-links with minoxidil restored thymic tissue expansion for hypoplast

50 Although an arterial vasodilator (minoxidil) resulted in significant pulmonary vasodilatio

51 logous concentrated platelet-rich plasma and minoxidil showed some benefit in AA, and phototherapy wi

52 SCR following prolonged therapy with topical Minoxidil solution and was treated with oral eplerenone.

53 Minoxidil solution has routinely been used for decades f

54 SCR as a possible consequence of the topical minoxidil solution.

55 Both topical and oral minoxidil, sometimes combined with antiandrogen therapy,

56 DOM, and the use of other off-label forms of minoxidil, such as compounded formulations of oral minox

57 avenous infusion of KCO912 (K(ATP) agonist), minoxidil sulfate (K(ATP) agonist) or NS1619 (K(Ca) agon

58 In a rat brain tumor model, we infused minoxidil sulfate (MS), a selective K(ATP) channel activ

59 ranscription quantitative PCR indicated that minoxidil sulfotransferase mRNA is also up-regulated in

60 Northern blot analysis indicated that minoxidil sulfotransferase mRNA is up-regulated in the f

61 The gene encoding the enzyme minoxidil sulfotransferase, an enzyme that catalyzes the

62 In vitro drug release of minoxidil sulphate from nanofiber exhibited an initial b

63 rospinning either blank (PVA) or loaded with minoxidil sulphate have yielded optimum fibers with an a

64 openers (diazoxide, pinacidil, chromakalim, minoxidil, testosterone) of the putative mitoKATP were a

65 ry of allergic contact dermatitis to topical minoxidil, the long-term safety of LDOM, and the use of

66 rative efficacy of topical minoxidil vs oral minoxidil, the safety of oral minoxidil for patients wit

67 ide-effect noted following prolonged topical minoxidil therapy for androgenic alopecia.

68 ide-effect noted following prolonged topical minoxidil therapy for androgenic alopecia.

69 include the comparative efficacy of topical minoxidil vs oral minoxidil, the safety of oral minoxidi

70 m2; 95% CI, 19.7-39.8 hairs/cm2]); 5 mg/d of minoxidil was significantly more efficacious than 1 mg/d

71 According to the photographic analysis, oral minoxidil was superior to topical minoxidil on the verte

72 The commonest treatment, minoxidil, was originally an antihypertensive drug that

73 ks (ie, second end point) was with 5 mg/d of minoxidil, which was significantly more efficacious than